Utrecht Holdings in action
These companies started within Utrecht University and/or the University Medical Center Utrecht with the assistance of Universiteit Utrecht Holding BV and/or UMC Utrecht Holding BV. In most cases these spin-off companies are based on intellectual property generated by Utrecht University and/or the University Medical Center Utrecht.
Prothix BV (2011) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Prothix is biotech company dedicated to the development of recombinant therapeutic proteins that address the medical need of patients with inflammatory and coagulation disorders. The company utilizes a so-called niche-buster strategy to capitalize its product portfolio.
Cristal Delivery BV (2011) (Universiteit Utrecht Holding BV)
Spin-off company of the Department of Pharmaceutics of Utrecht University, which is developing a proprietary product portfolio based on innovative combinations of its technology with new as well as marketed drugs. Cristal Delivery's nanoparticulate drug delivery platform increases efficacy, safety and convenience of pharmaceutical products through tuneable and controlled drug release inside the body.
Trajectum Pharma BV (2010) (Universiteit Utrecht Holding BV)
Spin-off company of the Faculty of Veterinary Medicine of Utrecht University, which focuses on the development of novel medicines for the treatment and prevention of inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease.
Simibio BV (2010) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Simibio BV was incorporated in 2010 by Dr. Mark de Boer and is an early stage company active in the development of therapeutic monoclonal antibodies. Utrecht Holdings is one of the participants in this company. Antibodies are an important part of the body's natural defense system and are normally produced by our immune system to help our bodies fight diseases such as cancer. Monoclonal antibodies are the dominant class of therapeutically important antibodies.
Universitaire Landbouwhuisdieren Praktijk BV (2009) (Universiteit Utrecht Holding BV)
Spin-off company as a result of the privatization of the Farm Animal Health Veterinary Practice of the Faculty of Veterinary Medicine which merged with a neighboring private veterinary practice to form one of the largest ruminant practices in the Netherlands. Apart from providing high quality and innovative animal-health care this practice will train future veterinarians in the University Farm-Animal Practice.
Thuja Capital Healthcare Fund BV (2007) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Thuja Capital a healthcare dedicated venture capital fund. Currently its fund capital is € 20 million. Thuja Capital is dedicated to investing venture capital in early-stage innovative healthcare companies. The focus will be on biotechnology and medical device companies. Thuja Capital has a rigorous and analytical investment process and a hands-on value creation approach and is active in the Benelux.
Cavadis (2007) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Cavadis is a biomedical company, established as a joint initiative by leading scientists at the department of Experimental Cardiology of the University Medical Centre of Utrecht and the department of Bioinformatics of the Erasmus MC Rotterdam. Cavadis' goal is to deliver diagnostic and therapeutic tools for the treatment of patients who are prone to develop unstable cardiovascular syndromes due to the presence of multiple thrombogenic vulnerable plaques.
U-Protein Express BV (2007) (Universiteit Utrecht Holding BV)
Dedicated CRO that has many years experience in recombinant protein production. At U-Protein Express BV fully post-translational modified mammalian recombinant proteins or recombinant antibodies are produced via its r-PEx transient expression platform.
Lead Pharma Holding BV (2007) (UMC Utrecht Holding BV)
Company focuses on the development and the commercialization of innovative therapeutics and nutraceuticals for human application.
Rabobank Pre-seed Fonds BV (2006) (Universiteit Utrecht Holding BV)
The Rabo Pre-seed fund offers personal loans against attractive and reasonable conditions to starters.
Milabs BV (2006) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Milabs develops and sells imaging systems, in particular to non-invasively monitor the dynamics and biodistribution of radiolabelled biomolecules. The first product is the U-SPECT (high resolution tomography system for three-dimensional imaging of molecule distributions and cell trafficking in living rodents).
RnA BV (2005) (Universiteit Utrecht Holding BV)
RnA provides diagnostic laboratories a new, innovative multi-analyte PlexTM assay to detect microbial and non-microbial contaminations simultaneously in a single sample in the animal production chain. Develops analytical methods to detect pathogens in the food chain to facilitate the production of food that is safe for consumers.
CrossBeta Biosciences BV (2005) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Spin-off that will focus on the development and diagnostics and therapeutics for protein accumulation diseases. Crossbeta Biosciences has broad intellectual property coverage of screening tools and for therapeutics in its areas of focus.
Enceladus BV (2005) (Universiteit Utrecht Holding BV)
Enceladus is a young and small-scale drug development company. Enceladus introduces Nanocort®, a liposomal pharmaceutical that contains an anti-inflammatory corticosteroid and selectively targets this drug to the actual sites of pathology in inflammatory disorders such as rheumatoid arthritis (RA) and multiple sclerosis (MS), and cancer.
GenDx (2005) (UMC Utrecht Holding BV)
Gen Dx (a tradename of Genome Diagnostics) aims to offer accurate and affordable diagnostic tools to facilitate donor/recipient matching, ultimately leading to higher success rates of bone-marrow, cord blood and stem cell transplantations.
Elana BV (2004) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
At the UMC Utrecht in 1993 Professor Tulleken invented a completely new way to make a neurovascular bypass without interrupting the blood flow in the recipient vessels. Elana sells the devices enabling this technique.
Nodens BV (2004) (Universiteit Utrecht Holding BV)
A holding company that holds stakes in Bioceros and PanGenetics.
Bioceros BV (2003) (Universiteit Utrecht Holding BV)
Biopharmaceutical R&D contract organization with experience in small R&D-oriented biopharmaceutical companies. The Company has a well-equipped laboratory.
BV Topselect Detacheringen (2003) (Universiteit Utrecht Holding BV)
Topselect BV (2000) (Universiteit Utrecht Holding BV)
Career counseling and job centre for Utrecht University.
PhytoGenix BV (2000) (Universiteit Utrecht Holding BV)
Phytogenix performs contract research for other companies by performing bioassays for the bio typing of biologically active compounds. Furthermore it focuses on the discovery of biologically active (plant-derived) lead compounds for further development into (phytogenic) drugs.
U-Clu BV (1998) (Universiteit Utrecht Holding BV)
Develops and sells in company training and advises on new educational tools for secundary schools and higher education.
Octopus BV (1996) (Universiteit Utrecht Holding BV and UMC Utrecht)
Company that exploits the rights of the successful Octopus technology and device that facilitates open-heart surgery. The technology and products are developed and marketed by the American company Medtronic Inc.
U-Cytech BV (1999) (Universiteit Utrecht Holding BV)
The company is engaged in fundamental and applied research in the field of cytokine biology. U-CyTech develops, manufactures and sells a wide range of innovative cytokine ELISA and ELISPOT systems for human, monkey and rodent use.
PanGenetics BV (1995) (Universiteit Utrecht Holding BV)
PanGenetics is a biopharmaceutical company that exploits its knowledge of the human immune system to develop novel proprietary antibody-based therapeutics for a variety of immune system-related diseases. The Company has a number of therapeutic monoclonal antibodies in pre-clinical and clinical development. Operations are based in Cambridge UK and in March 2006 PanGenetics successfully closed its series B venture capital financing round.
Selection of other spin-offs or former portfolio companies
These companies started within Utrecht University with the assistance of the Utrecht University Holding BV and/or were (partly) based on Utrecht University intellectual property.
Crucell NV (2000) / U-BiSys BV (1996) (Universiteit Utrecht Holding BV and UMC Utrecht Holding BV)
Crucell is the result of the merger between the Leiden based company IntroGene and the Utrecht spin-off U-BiSys (founded in 1996) in 2000. In the same year Crucell issued its IPO. Today Crucell N.V. is a leading European biotechnology company focusing on the development of vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies.
Promedas BV (2006) (UMC Utrecht Holding BV; exit 2011)
Promedas (PRObabilistic MEdical Diagnostic Advisory System) is a diagnostic decision support system used in health care.
Alant Vrouw BV (2002) (UMC Utrecht Holding BV; transferred to UMC Utrecht Exploitatie BV in 2010)
A private clinic founded by UMC Utrecht Holding BV and Alant Medical BV specialised in women's diseases.
Spoedkliniek voor Dieren Amsterdam (acquired in 2002 by Universiteit Utrecht Holding BV; exit 2008)
Emergency clinic for animals in Amsterdam. Provides veterinary care for pets. Was acquired by Utrecht University in 2002 to provide means to gain extra training positions and internships for its own veterinary students and veterinary doctors.
Semaia Pharmaceuticals BV (2000), UU/UMC Utrecht, acquired by Hybrigenics SA in 2003
Semaia specialized in the discovery and development of low molecular active substances that regulate defective intracellular signal transduction. These play a central role in the pathogenesis and growth of cancer. As a pioneer in the field of signal transduction, the company develops new drug candidates that demonstrate higher efficacy and, due to their target precision, produce fewer side effects.
GenMab BV/SA (2000), UU/ UMC Utrecht
GenMab is the largest biotechnology company in Utrecht that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. GenMab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. Genmab is headquartered in Copenhagen, Denmark and has its (pre-clinical) R&D operations in Utrecht. The company is partly built on intellectual property of CSO professor Jan van de Winkel of the UMC Utrecht.
OctoPlus BV (1995)
OctoPlus is a drug delivery and drug development company that is globally renowned for its expertise and professionalism. Since its inception in 1995 based on Utrecht intellectual property by professor Daan Crommelin, the company has established a successful track record and maintains partnerships with large and small biotech and pharma companies throughout the world. Its business activities include pharmaceutical development services, drug delivery technologies and product development.
U-Gene Research BV (1995), aquired by Kendle International in 1997
|
